Today's NewsMany posters were calling prior to this news that if a financial placement were announced it would be a miniscule amount as we see happened. This news of today I think puts us all at an elevated happy mood. What I really liked was the points of priority which to me says we are to see NSCLC & GBM moving forward. One cancer indication under the belt looking to bring that number to three and perhaps some movement in the virus therapeutic/vaccine.
The company intends to use the proceeds of the offering for the following:
- Good laboratory practice (GLP) toxicology study for intravenous installation of rutherrin intended for the treatment of non-small lung cancer (NSCLC) and glioblastoma multiforme (GBM);
- Advancement of phase 2 non-muscle invasive bladder cancer (NMIBC) clinical study;
- Working capital and general corporate purposes.